<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04110795</url>
  </required_header>
  <id_info>
    <org_study_id>AFF Control Study 18-6171</org_study_id>
    <nct_id>NCT04110795</nct_id>
  </id_info>
  <brief_title>Personalizing Osteoporosis Care: Clinical &amp; Genetic Risk Factors for AFFs</brief_title>
  <official_title>Personalizing Osteoporosis Care: Clinical &amp; Genetic Risk Factors for Atypical Femur Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this project is to identify clinical and genetic risk factors for
      Atypical Femur Fractures (AFFs) in Anti-resorptive therapy (ART) users by conducting a case
      control study of 330 cases of AFFs and 660 controls without AFFs matched for age, sex, race
      and duration of ART.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antiresorptive therapy (ART) drugs are effective osteoporosis treatment and help decrease
      osteoporosis-related fractures. However, their long-term use has been associated with rare
      but serious atypical femur fractures (AFFs). Fear of these side effects has caused a
      substantial decline in the use of these effective drugs and rising fracture rates. The
      investigators propose to compare 330 cases of people with AFFs to 660 matched controls to
      explore similarities and differences in (1) clinical findings, such as type of ART and length
      of use, prior fracture, bone density, femur geometry, etc., and (2) genetic variants, and
      then (3) to validate the top few genetic variants to see if they are indeed present in an
      additional group of 100 AFF patients and not present in 100 control subjects. This study will
      determine clinical and genetic risk factors for these debilitating atypical fractures such
      that at-risk patients in the future can be treated differently to avoid them.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Associations between AFF and clinical Risk Factor</measure>
    <time_frame>baseline</time_frame>
    <description>Associations between AFFs and clinical risk factors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Associations between AFF and common genetic variants</measure>
    <time_frame>baseline</time_frame>
    <description>Associations of common genetic variants among patients with AFFs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Validation of top genetic variants</measure>
    <time_frame>baseline</time_frame>
    <description>To validate the top few genetic variants identified in the above case-control study in a separate cohort of 100 cases and 100 controls.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Atypical Femur Fracture</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Atypical Femur fracture cases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>matched to AFF cases by race, age, length of ART use</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>No Intervention</description>
    <arm_group_label>Cases</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood samples serum samples fingernail samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Community based population in Ontario and British Columbia Canada
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cases: Have experienced a confirmed, documented Atypical femur fracture

          -  Controls: currently on anti-resorptive therapy, matches AFF case by age, race and
             length of ART use

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela M Cheung, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judy Scher, MSc</last_name>
    <phone>416-340-4841</phone>
    <email>Judy.Scher@uhnresearch.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Adachi Medical Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Reitsma</last_name>
      <phone>905-529-0612</phone>
    </contact>
    <investigator>
      <last_name>JD Adachi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bone Research &amp; Education Centre</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6M 1M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hajar Abu Alrob</last_name>
      <phone>905-844-5677</phone>
      <email>hajarabualrob@boneresearch.ca</email>
    </contact>
    <investigator>
      <last_name>Aliya Khan, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network, TGH</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sameh Melk</last_name>
      <phone>416-340-4800</phone>
      <phone_ext>5703</phone_ext>
      <email>Sam.melk@uhnresearch.ca</email>
    </contact>
    <investigator>
      <last_name>Angela MW Cheung, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lianne E Tile, MD, ME</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Femoral Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

